The PHASE 3 REVISIT study has demonstrated that aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ventilator-associated pneumonia ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

Emblaveo (aztreonam-avibactam) was approved for treating complicated intra-abdominal infections with limited or no treatment ...

AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...